0HS8 Stock Overview
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lisata Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.86 |
| 52 Week High | US$3.74 |
| 52 Week Low | US$2.12 |
| Beta | 1.22 |
| 11 Month Change | -1.72% |
| 3 Month Change | n/a |
| 1 Year Change | 17.46% |
| 33 Year Change | -79.93% |
| 5 Year Change | n/a |
| Change since IPO | -95.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HS8 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 4.6% | 0.3% | 2.2% |
| 1Y | 17.5% | -18.3% | 8.0% |
Return vs Industry: 0HS8 exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0HS8 exceeded the UK Market which returned 8% over the past year.
Price Volatility
| 0HS8 volatility | |
|---|---|
| 0HS8 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HS8's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0HS8's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 25 | Dave Mazzo | www.lisata.com |
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Lisata Therapeutics, Inc. Fundamentals Summary
| 0HS8 fundamental statistics | |
|---|---|
| Market cap | US$23.96m |
| Earnings (TTM) | -US$20.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 0HS8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HS8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.74m |
| Earnings | -US$20.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0HS8 perform over the long term?
See historical performance and comparison